Cellergy Pharma
Manufacturing · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Powder Mill Rd, Wilmington, Delaware...Website
www.cellergypharma.comRevenue
<$5 MillionIndustry
About Cellergy Pharma
Cellergy Pharma Org Chart
Is Cellergy Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cellergy Pharma had a recent Job posting/layoffs
Check if Cellergy Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cellergy Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Cellergy Pharma launches new products
Earning: See what the market has to say on Cellergy Pharma recently announced quarterly report
Cellergy Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Cellergy Pharma
Check out if Cellergy Pharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Cellergy Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellergy Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellergy Pharma.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellergy Pharma
Cellergy Pharma is developing a first-in-class CAR T cell immunotherapy aimed at treating severe allergic diseases, specifically targeting IgE-producing cells. The company is pioneering the use of CAR T cells beyond cancer treatment to address immune-mediated diseases. Their focus is on two significant underserved markets: uncontrollable severe all... Read More